EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other

Mengya Jiao, Yan Sun, Junyu Shi, Na Zhang, Xuhuan Tang, Anqi Fan, Shiwang Liu, Chan Dai, Zhigang Qian, Feng Zhang, Chenchen Wang, Huoying Chen and 1 more

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110653 ↗

At a glance

Journal article in International Immunopharmacology, 2023. Written by Mengya Jiao and 12 co-authors. Institution: Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic I…. Major MEDLINE topics: Encephalomyelitis, Autoimmune, Experimental, HMGB1 Protein. Cited 7 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Interleukin-33 (IL-33) and high mobility group box 1 (HMGB1) have been reported to play crucial and distinct roles in experimental autoimmune encephalomyelitis (EAE). However, little is known about their interaction in the progression of EAE. In this study, the dynamic expression and release of IL-33 and HMGB1 in different stages of EAE in vivo, and their interaction in vitro were explored. We found that HMGB1 was dominant in pre-onset stage of EAE, while IL-33 was dominant in peak stage. Moreover, both blockade of extracellular HMGB1 in the central nervous system (CNS) and conditional knockout of HMGB1 in astrocytes decreased IL-33 release. HMGB1 promoted the release of IL-33, while IL-33 reduced the release of HMGB1 from primary astrocytes in vitro. Taken together, IL-33 and HMGB1 in the CNS jointly participate in the EAE progression and the inhibitory effect of IL-33 on HMGB1 may be involved in the self-limiting of EAE.

Subjects

MeSH terms (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalHMGB1 ProteinAnimalsMiceInterleukin-33Central Nervous SystemAstrocytesMice, Inbred C57BL

Author keywords

AstrocytesEAEHMGB1IL-33

Substances

Interleukin-33HMGB1 Protein

Authors and institutions

  • Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology, Wuha…
  • Wuhan Institute for Neuroscience and Neuroengineering, South-Central Minzu University, Wuhan 430074, China; College of Life Sciences, South-Central Minzu University, Wuhan 430074, China.
  • Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475004, China.
  • College of Life Science, Yangtze University, Jingzhou 434025, China.
  • National Demonstration Center for Experimental Basic Medical Education, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: wangchenj…
  • Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China; Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affili…

Cite

APA

Jiao, M., Sun, Y., Shi, J., Zhang, N., Tang, X., Fan, A., Liu, S., Dai, C., Qian, Z., Zhang, F., Wang, C., Chen, H., & Zheng, F. (2023). IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110653

Vancouver

Jiao M, Sun Y, Shi J, Zhang N, Tang X, Fan A, et al. IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110653

BibTeX
@article{Jiao2023,
  author = {Jiao, Mengya and Sun, Yan and Shi, Junyu and Zhang, Na and Tang, Xuhuan and Fan, Anqi and Liu, Shiwang and Dai, Chan and Qian, Zhigang and Zhang, Feng and Wang, Chenchen and Chen, Huoying and Zheng, Fang},
  title = {IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110653}
}
Start for free →